Jubilant Pharmova Intrinsic Value
JUBLPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹667.92 | ₹534.34 - ₹801.50 | -37.2% | EPS: ₹30.36, Sector P/E: 22x |
| Book Value Method | asset | ₹2660.50 | ₹2394.45 - ₹2926.55 | +150.0% | Book Value/Share: ₹3899.38, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2128.40 | ₹1915.56 - ₹2341.24 | +100.0% | Revenue/Share: ₹4920.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2128.40 | ₹1915.56 - ₹2341.24 | +100.0% | EBITDA: ₹1348.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2660.50 | ₹2128.40 - ₹3192.60 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹319.26 | ₹287.33 - ₹351.19 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹469.06 | ₹422.15 - ₹515.97 | -55.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2128.40 | ₹1915.56 - ₹2341.24 | +100.0% | ROE: 7.7%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹1632.07 | ₹1468.86 - ₹1795.28 | +53.4% | EPS: ₹30.36, BVPS: ₹3899.38 |
Want to compare with current market value? Check JUBLPHARMA share price latest .
Valuation Comparison Chart
JUBLPHARMA Intrinsic Value Analysis
What is the intrinsic value of JUBLPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jubilant Pharmova (JUBLPHARMA) is ₹2128.40 (median value). With the current market price of ₹1064.20, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹319.26 to ₹2660.50, indicating ₹319.26 - ₹2660.50.
Is JUBLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Jubilant Pharmova (JUBLPHARMA) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.82 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.04 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 7.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.62x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Jubilant Pharmova
Additional stock information and data for JUBLPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,072 Cr | ₹1,072 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹971 Cr | ₹673 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹661 Cr | ₹424 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹838 Cr | ₹677 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,784 Cr | ₹1,421 Cr | Positive Free Cash Flow | 8/10 |